CVE:DXD

3D Signatures Competitors

C$0.04
+0.04 (+∞)
(As of 04/5/2019)
Add
Compare
Today's Range
C$0.04
Now: C$0.04
C$0.04
50-Day Range
C$0.04
MA: C$0.04
C$0.04
52-Week Range
C$0.03
Now: C$0.04
C$0.25
Volume5,000 shs
Average Volume30,759 shs
Market CapitalizationC$2.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

3D Signatures (CVE:DXD) Vs. AKU, LXG, SQD, SVA, GEN, and LMD

Should you be buying DXD stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to 3D Signatures, including Akumin (AKU), LexaGene (LXG), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), and LED Medical Diagnostics (LMD).

Akumin (TSE:AKU) and 3D Signatures (CVE:DXD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Profitability

This table compares Akumin and 3D Signatures' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
3D SignaturesN/AN/AN/A

Valuation and Earnings

This table compares Akumin and 3D Signatures' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminC$246.08 million1.08C$-25,263,475.00C($0.37)-10.55
3D SignaturesN/AN/AN/AC($0.04)-0.91

3D Signatures has lower revenue, but higher earnings than Akumin. Akumin is trading at a lower price-to-earnings ratio than 3D Signatures, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Akumin and 3D Signatures, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin01102.50
3D Signatures0000N/A

Akumin presently has a consensus target price of C$4.25, suggesting a potential upside of 10.39%. Given Akumin's higher possible upside, analysts clearly believe Akumin is more favorable than 3D Signatures.

Summary

Akumin beats 3D Signatures on 3 of the 5 factors compared between the two stocks.

LexaGene (CVE:LXG) and 3D Signatures (CVE:DXD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for LexaGene and 3D Signatures, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LexaGene0000N/A
3D Signatures0000N/A

Earnings and Valuation

This table compares LexaGene and 3D Signatures' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneN/AN/AN/AC($0.12)-6.39
3D SignaturesN/AN/AN/AC($0.04)-0.91

LexaGene is trading at a lower price-to-earnings ratio than 3D Signatures, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LexaGene and 3D Signatures' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LexaGeneN/AN/AN/A
3D SignaturesN/AN/AN/A

Summary

3D Signatures beats LexaGene on 2 of the 2 factors compared between the two stocks.

SQI Diagnostics (CVE:SQD) and 3D Signatures (CVE:DXD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Earnings and Valuation

This table compares SQI Diagnostics and 3D Signatures' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQI DiagnosticsC$977,000.00111.59C$-12,264,984.00C($0.04)-8.89
3D SignaturesN/AN/AN/AC($0.04)-0.91

3D Signatures has lower revenue, but higher earnings than SQI Diagnostics. SQI Diagnostics is trading at a lower price-to-earnings ratio than 3D Signatures, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SQI Diagnostics and 3D Signatures' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQI DiagnosticsN/AN/AN/A
3D SignaturesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for SQI Diagnostics and 3D Signatures, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQI Diagnostics0000N/A
3D Signatures0000N/A

Summary

SQI Diagnostics beats 3D Signatures on 2 of the 3 factors compared between the two stocks.

3D Signatures (CVE:DXD) and Sernova (CVE:SVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares 3D Signatures and Sernova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
3D SignaturesN/AN/AN/AC($0.04)-0.91
SernovaN/AN/AN/AC($0.03)-54.81

Sernova is trading at a lower price-to-earnings ratio than 3D Signatures, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 3D Signatures and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
3D SignaturesN/AN/AN/A
SernovaN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for 3D Signatures and Sernova, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
3D Signatures0000N/A
Sernova0000N/A

3D Signatures (CVE:DXD) and GeneNews (TSE:GEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares 3D Signatures and GeneNews' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
3D SignaturesN/AN/AN/AC($0.04)-0.91
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

3D Signatures has higher earnings, but lower revenue than GeneNews. 3D Signatures is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for 3D Signatures and GeneNews, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
3D Signatures0000N/A
GeneNews0000N/A

Profitability

This table compares 3D Signatures and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
3D SignaturesN/AN/AN/A
GeneNewsN/AN/AN/A

Summary

3D Signatures beats GeneNews on 2 of the 3 factors compared between the two stocks.

LED Medical Diagnostics (CVE:LMD) and 3D Signatures (CVE:DXD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares LED Medical Diagnostics and 3D Signatures' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26
3D SignaturesN/AN/AN/AC($0.04)-0.91

3D Signatures has lower revenue, but higher earnings than LED Medical Diagnostics. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than 3D Signatures, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for LED Medical Diagnostics and 3D Signatures, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LED Medical Diagnostics0000N/A
3D Signatures0000N/A

Profitability

This table compares LED Medical Diagnostics and 3D Signatures' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LED Medical DiagnosticsN/AN/AN/A
3D SignaturesN/AN/AN/A

Summary

LED Medical Diagnostics beats 3D Signatures on 2 of the 3 factors compared between the two stocks.


3D Signatures Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKU
Akumin
0.9$3.85+2.6%C$266.48 millionC$246.08 million-10.55
LXG
LexaGene
0.5$0.76+1.3%C$83.27 millionN/A-6.39News Coverage
SQD
SQI Diagnostics
0.9$0.32+9.4%C$52.59 millionC$977,000.00-8.89
SVA
Sernova
0.5$1.48+2.7%C$31.35 millionN/A-54.81Gap Down
GEN
GeneNews
0.5N/AN/AC$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40+100.0%C$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics
0.6$0.56+8.9%C$5.58 millionC$37,517.00-16.97
IDL
Imaging Dynamics
0.4$0.08+13.3%C$4.13 millionC$378,253.00-3.95Gap Down
MBI
Med Biogene
0.5$0.05+22.2%C$795,000.00N/A-7.50Gap Up
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.